Catawba Capital Management’s Biogen BIIB Stock Holding History

Catawba Capital Management’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	$387K	Buy	1,335 +25	+2%	+$7.03K	0.09%	154
2018 Q1	$359K	Sell	1,310 -140	-10%	-$43.5K	0.09%	156
2017 Q4	$462K	Buy	1,450 +295	+26%	+$94.6K	0.1%	140
2017 Q3	$362K	Buy	1,155 +295	+34%	+$87.4K	0.08%	168
2017 Q2	$233K	Hold	860	–	–	0.05%	211
2017 Q1	$235K	Hold	860	–	–	0.05%	233
2016 Q4	$244K	Buy	860 +170	+25%	+$50.4K	0.06%	220
2016 Q3	$216K	Buy	+690	New	+$204K	0.05%	228

Other funds holding BIIB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Catawba Capital Management's BIIB Position: Q2 2018 in Review

Catawba Capital Management increased its Biogen (BIIB) stake by 1.9% in Q2 2018, buying an estimated $7.03K and bringing the position to 1,335 shares worth $387K. The position accounts for 0.09% of the portfolio, ranked #154.

Catawba Capital Management first reported a position in BIIB in Q3 2016 and has held it in 8 quarters since. The position peaked at $462K in Q4 2017. 1,098 funds tracked by Wall St. Rank hold BIIB as of Q2 2018.

Catawba Capital Management held 1,335 shares of Biogen worth $387K as of Q2 2018.
Catawba Capital Management bought 25 Biogen shares in Q2 2018, an estimated $7.03K.
Biogen made up 0.09% of Catawba Capital Management's portfolio in Q2 2018, its #154 holding.
Catawba Capital Management first reported a position in Biogen in Q3 2016 and has held it in 8 quarters since.
Catawba Capital Management's Biogen position peaked at $462K in Q4 2017.
1,098 funds tracked by Wall St. Rank held Biogen as of Q2 2018.

Based on Catawba Capital Management's 13F filing for Q2 2018, filed 11 Jul 2018.